Cerenome, Inc.
Prices may be delayed up to 15 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| CNSY | RADX | CLRB | LTRN | PCSA | ALLR | |
|---|---|---|---|---|---|---|
| Market cap | 13.74M | 16.20M | 13.52M | 11.01M | 5.31M | 13.68M |
| P/E (TTM) | — | — | — | — | — | — |
| Forward P/E | -0.7 | -0.5 | -0.7 | -0.4 | -0.5 | -1.0 |
| Price/book | 2.4 | 0.7 | 0.4 | -2.9 | -16.7 | 3.9 |
| Dividend yield | — | — | — | — | — | — |
| 1-year change | −88.65% | −84.08% | −70.35% | −81.56% | −86.21% | −43.42% |
| Today | −6.22% | −2.63% | −1.38% | −9.31% | +25.00% | −13.12% |
The closest companies by business and industry (Biotechnology). Prices may be delayed up to 15 min.
Latest news
All CNSY news ›Cerenome Secures In-Network Agreement with Florida Blue for CNSide® CSF Tumor Cell Enumeration and Molecular Profile Tests
The agreement adds approximately 6 million covered lives, bringing CNSide’s contracted payer footprint to approximately 164 million commercial and Medicare Advantage covered lives. The CSF Molecular Profile tests are now commercially…
Cerenome Launches Two CSF Molecular Profiling Tests for CNS Cancers
Oct 7, 2026 | Cancer, Molecular Diagnostics | CNSide Diagnostics, a subsidiary of Cerenome, has commercially launched two new cerebrospinal fluid (CSF)-based molecular profiling tests for central nervous system (CNS) oncology. Available to…
Cerevance
The rich text element allows you to create and format headings, paragraphs, blockquotes, images, and video all in one place instead of having to add and format them individually. Just double-click and easily create content. A rich text…
Cerenome Selects XiFin Empower RCM for Revenue Cycle Management and Clearinghouse Services for CNSide Platform
Scalable revenue cycle ecosystem designed to support anticipated billing volumes; CNSide assay billing to begin in Q3 2026 with accumulated 2026 backlog of tests and concurrent case billing The CNSide® CSF Assay Platform supports rapid…
Cerenome updates investor presentation; commercial CNSide traction, REYOBIQ Phase 2 readouts and Medicare rate expected
TradingView Cerenome updates investor presentation; commercial CNSide traction, REYOBIQ Phase 2 readouts and Medicare rate expected Cerenome updated its corporate presentation highlighting CNSide commercial progress, upcoming REYOBIQ Phase…
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform Transcript
Cerenome, Inc. (CNSY) Discusses Diagnostic Division Update and Progress on C-INSIDE Platform September 30, 2026 8:30 AM EDTCompany ParticipantsMarc Hedrick...
Cerenome Expects $1.55 Million in CNSide® Third Quarter Gross Billings
Lead test on track for 200 million covered lives and beneficiaries by early 2027 after CMS meeting On track to launch expanded CNSide testing menu with multiple tests in Q4 2026 HOUSTON, Sept. 30, 2026 (GLOBE NEWSWIRE) -- Cerenome, Inc.…
Cerenome Reports CNSide Q3 2026 Progress on Coverage Expansion, Medicare Pricing and Testing Menu Growth | CNSY Stock News
CNSide's Tumor Cell Enumeration Test is contracted for 158 million covered lives and is on track for 200 million by early 2027. The expanded CNSide testing menu, including new tests, is expected to launch in Q4 2026. CNSide billed 222…
From articles in the 4Search news index.
In the news
Mentioned with
People in the coverage
Most coverage from
-
manilatimes.net3
-
quiverquant.com2
-
marketscreener.com1
-
pulse2.com1
-
seekingalpha.com1
Finance and business coverage in the 4Search news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 10 articles, not a forecast.